Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds expression product or fragment thereof of...
Reexamination Certificate
2003-10-15
2008-09-30
Helms, Larry (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds expression product or fragment thereof of...
C424S130100, C424S141100, C424S178100, C424S181100, C530S387100, C530S387900, C530S388100, C530S388800
Reexamination Certificate
active
07429382
ABSTRACT:
The present invention provides antibodies, and antigen-binding fragments of antibodies, fusion polypeptides and analogs that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides. The present invention further provides methods of preventing, managing, treating or ameliorating one or more symptoms associated with a CA 125/O772P-related disorder. In particular, the present invention provides methods of preventing, managing, treating, or ameliorating one or more symptoms associated with a cell proliferative disorder, such as cancer, e.g., ovarian cancer. The present invention still further provides methods for diagnosing a CA 125/O772P-related disorder or predisposition to developing such a disorder, as well as methods for identifying antibodies, and antigen-binding fragments of antibodies, that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides.
REFERENCES:
patent: 4921790 (1990-05-01), O'Brien
patent: 5059680 (1991-10-01), Davis et al.
patent: 5366866 (1994-11-01), Xu et al.
patent: 5486456 (1996-01-01), Xu et al.
patent: 5650291 (1997-07-01), Lee
patent: 5693762 (1997-12-01), Queen et al.
patent: 5858361 (1999-01-01), Wagner et al.
patent: 5871941 (1999-02-01), Auersperg
patent: 5976818 (1999-11-01), O'Brien
patent: 6136310 (2000-10-01), Hanna et al.
patent: 6241985 (2001-06-01), Madiyalakan et al.
patent: 6376654 (2002-04-01), Gelber
patent: 6468546 (2002-10-01), Mitcham et al.
patent: 6488931 (2002-12-01), Mitcham et al.
patent: 6528253 (2003-03-01), Mitcham et al.
patent: 6670463 (2003-12-01), Mitcham et al.
patent: 6699664 (2004-03-01), Mitcham et al.
patent: 2002/0009451 (2002-01-01), O'Brien
patent: 2002/0022591 (2002-02-01), Algate et al.
patent: 2002/0037287 (2002-03-01), Gelber
patent: 2002/0081609 (2002-06-01), Dillon et al.
patent: 2002/0119158 (2002-08-01), Algate et al.
patent: 2003/0008299 (2003-01-01), Algate
patent: 2003/0082655 (2003-05-01), O'Brien
patent: 2003/0091580 (2003-05-01), Mitcham et al.
patent: 2003/0104442 (2003-06-01), Lloyd et al.
patent: 2003/0124140 (2003-07-01), Bangur et al.
patent: 2003/0165504 (2003-09-01), Retter et al.
patent: 2004/0127401 (2004-07-01), O'Brien
patent: 0 332 651 (1996-12-01), None
patent: 1256354 (2002-11-01), None
patent: WO89/01629 (1989-02-01), None
patent: WO94/27637 (1994-08-01), None
patent: WO96/31539 (1996-10-01), None
patent: WO00/36107 (2000-06-01), None
patent: WO 00/36107 (2000-06-01), None
patent: WO0036107 (2000-06-01), None
patent: WO01/40269 (2001-06-01), None
patent: WO01/60860 (2001-08-01), None
patent: WO0157207 (2001-08-01), None
patent: WO01/70804 (2001-09-01), None
patent: WO01/70979 (2001-09-01), None
patent: WO01/75177 (2001-10-01), None
patent: WO01/85203 (2001-11-01), None
patent: WO02/00677 (2002-01-01), None
patent: WO0206317 (2002-01-01), None
patent: WO0207783 (2002-01-01), None
patent: WO02/071928 (2002-09-01), None
patent: WO02/074961 (2002-09-01), None
patent: WO02/076384 (2002-10-01), None
patent: WO02083866 (2002-10-01), None
patent: WO02/092836 (2002-11-01), None
patent: WO02092836 (2002-11-01), None
patent: WO03076465 (2003-09-01), None
patent: WO03076473 (2003-09-01), None
patent: WO2004005470 (2004-01-01), None
patent: WO2004045553 (2004-06-01), None
patent: PCT/US03/32945 (2004-08-01), None
(American Heritage Dictionary of the English Language, 4th Ed., 2000, p. 1-2).
(MSN Encarta, Dictionary, p. 1-2).
Berger et al (Cancer Biotherapy & Radiopharmaceuticals, 2005, 20:589-602).
Janeway et al (Immunobiology, 2001, 5th Ed., Garland Publishing, New York).
(Rudikoff et al, PNAS, USA, 1982, 79: 1979).
Yin and Lloyd, Journal of Biological Chemistry, Jul. 2001, 276:27371-27375.
O'Brien et al (Tumour Biol, 2001, 22:348-66).
Bast et al. (1981) “Reactivity of a Monoclonal Antibody with Human Ovarian Cacrcin”J. Clin Invest68(5): 1331-37.
Boshell et al. (1992) “The Product of the Human MUC1 Gene When Secreted by Mouse Cells Transfected With the Full-Length cDNA Lacks Cytoplasmic Tail”Biocehm and Biophys Res. Comm185(1):1-8.
Frailes et al. (1993) “Purification and Characterization of the CA 125 Tumor-Associated Antigen From Human Ascites” Tumour Biol. 1993;14(1):18-29.
Gadducci et al., (1992) :“The Concomitant Determination of Different Tumor Markers in Patients with Epithelial Ovarian Cancer and Benign Ovarian Masses: Relevance for Differential Diagnosis”,Gynecol Oncol. 44(2):147-54.
Hovig et al. (2001) “CA125: The End of the Beginning”Tumor Bio. 22:345-47.
Hu et al. (2003) “Discovery and Validation of New Molecular Targets of Ovarian Cancer”Current Opinion in Molecular Therapeutics. 5(6):625-630.
Kabawat et al. (1983) “Immunopathologic Characterization of a Monoclonal Antibody That Recognizes Common Surface Antigens of Human Ovarian Tumors of Serous, Endometrioid, and Clear Cell Types”, Am. J. Clin. Pathol. 79:98-104.
Lightenberg et al. (1992) “Cell-Associated Episialin Is a Complex Containing Two Proteins Derived From A Common Precursor”The Journal of Biol. Chem.. 267(9):6171-77.
Madiyalakan et al. (1997) “Ovarex MAb-B43.13:IFN-Gamma Could Improve the Ovarian Tumor Cell Sensitivity to CA125-Specific Allogenic Cytotoxic T Cell”Hybridoma16(1): 41-5.
Maeda et al. (2004) “Solution Structure of the SEA Domain From the Murine Homologue of Ovarian Cancer Antigen CA125 (MUC16)”The Journal of Biol. Chem.. 279(13): 13174-13182.
Noujaim et al. (2001) “Induction of CA125-Specific B and T Cell Responses in Patients Injected With MAb-B43.13—Evidence for Antibody-Mediated Anti-processing and Presentation of CA125 in Vivo”Cancer Biother. Radiopharm16(3): 187-203.
Nustad et al. (1996) “Specificity and Affinity of 26 Monoclonal Antibodies Against the CA 125 Antigen: First Report From the ISOBM TD-1 Workshop. International Society for Oncodevelopmental Biology and Medicine”Tumour Biol. 17(4): 196-219.
Nustad et al. (2002) “Epitopes on CA 125 From Cervical Mucus and Ascites Fluid and Characterization of Six New Antibodies. Third report from the ISOBM TD-1 workshop”Tumour Biol. 23(5): 303-314.
O'Brien et al. (2001) “The CA125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences”Tumor Bio. 22:348-366.
O'Brien et al. (2002) “The CA125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular Superstructure”Tumor Bio. 23:154-169.
Saga et al. (1990) “Construction of an Immunoradiometric Assay for Ovarian Cancer Antigen CA125 Recognizing Different Antigenic Determinant”Acta Obstet Gynecol. Scand. 69(2):175-81.
Saga et al. (1990) “An Antibody-Tumor Model for the Targeting of CA125-Producing Gynecologic Malignancies”Jpn J. Cancer Res.. 81(11):1141-48.
Yin et al. (2001) “Molecular Cloning of the CA125 Ovarian Cancer Antigen”The Journal of Biol. Chem. 276(29):27371-375.
Andersson, et al., 1999 “Biokinetics of the Monoclonal Antibodies MOv 18, OV 185 and OV 197 Labelled with125I According to the m-MeATE Method or the Iodogen Method in Nude Mice with Ovarian Cancer Xenografts” ,ACTA Oncologica, 38(3) 323-328.
Bouvier, et al., 1988 “Serum Levels of Tumor Markers and Presence of Human Antimouse Antibodies: Implications for Diagnosis and Treatment with Radiolabeled Monoclonal Antibodies”,Cancer Detection and Prevention, 13: 251-262.
Chatal, et al., 1989 “Biodistribution of Indium-111-Labeled OC 125 Monoclonal Antibody Intraperitoneally Injected Into Patients Operated On for Ovarian Carcinomas”,Cancer Research, 49: 3087-3094.
Cuesta, et al., 1999 “Tissue Quantifications of CA 125 in Epithelial Ovarian Cancer”,The International Journal of Biological Markers, 14(2): 106-114.
Gaetje, et al., 1999 “Ovarian Cancer Antigen CA 125 Enhances the Invasiveness of the Endometriotic Cell Line EEC 145”,J. Soc. Gynecol. Invest., 6(5): 278-281.
Albone Earl F.
Soltis Daniel A.
Corixa Corporation
Goddard Laura B
Helms Larry
Seed IP Law Group PLLC
LandOfFree
Antibodies that bind cell-associated CA 125/O772P and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies that bind cell-associated CA 125/O772P and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies that bind cell-associated CA 125/O772P and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3970343